News | August 31, 2022
Cipla (EU) to acquire an additional 13.10% stake in Cipla (Jiangsu) Pharmaceutical
Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.
Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.
WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
Subscribe To Our Newsletter & Stay Updated
